Musculoskeletal Disorders
Atom Bioscience reports positive Phase IIa chronic gout therapy trial data
Atom Bioscience has reported positive data from its China Phase IIa study of ABP-671 for the treatment of chronic gout.…
Incannex begins Phase II trial of combination drug for rheumatoid arthritis
Incannex Healthcare has commenced a Phase II clinical trial of its anti-inflammatory combination drug IHL-675A in patients with rheumatoid arthritis…
Maze Therapeutics reports positive data from Pompe disease therapy trial
Maze Therapeutics has reported positive data from its Phase I clinical trial of oral glycogen synthase (GYS1) inhibitor MZE001 in…
Avidity reports data from Phase I/II myotonic dystrophy type 1 trial
Avidity Biosciences has reported positive initial analysis data from the Phase I/II MARINA clinical trial of AOC 1001 in adults…
Pipeline Moves: trial completions in glaucoma, lung, and oncology indications
This week on Pipeline Moves, we look into the completion of a Phase III trial in open-angle glaucoma. For Phase…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Peptilogics doses first subject in periprosthetic joint infection trial
Peptilogics has dosed the first subject in the Phase Ib LOGIC-1 clinical trial of investigational product PLG0206 to treat periprosthetic joint infections…
Avidity launches Phase I/II muscular dystrophy treatment trial
Avidity Biosciences has launched the Phase I/II FORTITUDE clinical trial of AOC 1020 in adult patients with facioscapulohumeral muscular dystrophy…
FDA places partial hold on Avidity’s Phase I/II myotonic dystrophy trial
The US Food and Drug Administration (FDA) has placed a partial hold on Avidity Biosciences’ Phase I/II MARINA clinical trial of AOC…
Atamyo doses first subject in Phase I/II muscular dystrophy therapy trial
Atamyo Therapeutics has dosed the first subject in a Phase I/II clinical trial of ATA-100 to treat FRKP-related limb-girdle muscular dystrophy type…
Santhera and ReveraGen dose first subject in Phase II trial of BMD drug
Santhera Pharmaceuticals and ReveraGen BioPharma have dosed the first subject in a Phase II pilot clinical trial of drug candidate…